JP2012520302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520302A5 JP2012520302A5 JP2011554083A JP2011554083A JP2012520302A5 JP 2012520302 A5 JP2012520302 A5 JP 2012520302A5 JP 2011554083 A JP2011554083 A JP 2011554083A JP 2011554083 A JP2011554083 A JP 2011554083A JP 2012520302 A5 JP2012520302 A5 JP 2012520302A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- fluorodibenzo
- oxepin
- oxazin
- ylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- CZHIJMGMBQCQDA-ISGJEAITSA-N 3-[(7r,8ar)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[2,1-c][1,4]oxazin-7-yl]-6-[(e)-(3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene)methyl]-1h-benzimidazol-2-one Chemical compound C=1C(F)=CC=C2C=1OCC1=CC=CC=C1\C2=C/C1=CC=C(N([C@H]2CN3CCOC[C@H]3C2)C(=O)N2)C2=C1 CZHIJMGMBQCQDA-ISGJEAITSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15957809P | 2009-03-12 | 2009-03-12 | |
| US61/159,578 | 2009-03-12 | ||
| PCT/US2010/026138 WO2010104721A1 (en) | 2009-03-12 | 2010-03-04 | Mineralocorticoid receptor antagonist and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520302A JP2012520302A (ja) | 2012-09-06 |
| JP2012520302A5 true JP2012520302A5 (enExample) | 2013-04-11 |
| JP5570536B2 JP5570536B2 (ja) | 2014-08-13 |
Family
ID=42139981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554083A Expired - Fee Related JP5570536B2 (ja) | 2009-03-12 | 2010-03-04 | 鉱質コルチコイド受容体アンタゴニストおよび使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8658638B2 (enExample) |
| EP (1) | EP2406252B1 (enExample) |
| JP (1) | JP5570536B2 (enExample) |
| KR (1) | KR101312179B1 (enExample) |
| CN (1) | CN102333773B (enExample) |
| AU (1) | AU2010222902B2 (enExample) |
| BR (1) | BRPI1009257A2 (enExample) |
| CA (1) | CA2751901C (enExample) |
| EA (1) | EA019179B1 (enExample) |
| ES (1) | ES2542001T3 (enExample) |
| MX (1) | MX2011009506A (enExample) |
| WO (1) | WO2010104721A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| RS58274B1 (sr) | 2014-06-30 | 2019-03-29 | Astrazeneca Ab | Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| WO2018019843A1 (en) | 2016-07-26 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| JP7697961B2 (ja) | 2020-03-11 | 2025-06-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。 |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| MXPA06007055A (es) * | 2003-12-19 | 2007-01-30 | Lilly Co Eli | Moduladores del receptor nuclear de hormona esteroide triciclica. |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
-
2010
- 2010-03-04 US US13/203,518 patent/US8658638B2/en not_active Expired - Fee Related
- 2010-03-04 CN CN201080009314.8A patent/CN102333773B/zh not_active Expired - Fee Related
- 2010-03-04 EP EP20100707770 patent/EP2406252B1/en not_active Not-in-force
- 2010-03-04 CA CA2751901A patent/CA2751901C/en not_active Expired - Fee Related
- 2010-03-04 AU AU2010222902A patent/AU2010222902B2/en not_active Ceased
- 2010-03-04 EA EA201171125A patent/EA019179B1/ru not_active IP Right Cessation
- 2010-03-04 KR KR1020117021231A patent/KR101312179B1/ko not_active Expired - Fee Related
- 2010-03-04 JP JP2011554083A patent/JP5570536B2/ja not_active Expired - Fee Related
- 2010-03-04 ES ES10707770.3T patent/ES2542001T3/es active Active
- 2010-03-04 MX MX2011009506A patent/MX2011009506A/es active IP Right Grant
- 2010-03-04 WO PCT/US2010/026138 patent/WO2010104721A1/en not_active Ceased
- 2010-03-04 BR BRPI1009257A patent/BRPI1009257A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522816A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2013531028A5 (enExample) | ||
| JP2012520302A5 (enExample) | ||
| JP2013543896A5 (enExample) | ||
| JP2013507408A5 (enExample) | ||
| JP2015531774A5 (enExample) | ||
| JP2010536849A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2010511621A5 (enExample) | ||
| JP2006298933A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2010502730A5 (enExample) | ||
| JP2011516477A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| EA201070598A1 (ru) | Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht | |
| JP2009538861A5 (enExample) | ||
| PH12018500261A1 (en) | Azole benzene derivative | |
| JP2012507535A5 (enExample) | ||
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
| JP2013166781A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| JP2009062388A5 (enExample) | ||
| JP2013539774A5 (enExample) |